Fed. Circ. Revives Patents In IP Suit Over Opioid Generic
The Federal Circuit partly reversed a lower court decision Wednesday regarding the validity of three BioDelivery Sciences patents asserted against Alvogen in litigation over the opioid drug Belbuca, determining that the...To view the full article, register now.
Already a subscriber? Click here to view full article